The investigation was the result of watchdog activity by the Anti-Corruption Action Center in partnership with Ukrainian lawmakers who are members of the Global Organization of Parliamentarians Against Corruption.
Indar was established in 1997 exclusively to produce affordable and inexpensive insulin, which the company did until 2012. But that year Indar started to win health ministry bids for the supply of new, yet untypical medicines for the plant, in particular medicine for antiretroviral therapy and tuberculosis treatment.
Several public statements by the director, Vyshnevska, accompanied this new development and claimed the plant’s production line of medicines had been expanded. In particular, Vyshnevska more than once announced that the plant would start producing medicine locally for the Chicago-based pharmaceuticals company Abbott Laboratories.